CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group Limited has announced that its drug JMT202, a recombinant fully human anti-βKlotho monoclonal antibody, has received approval from the U.S. FDA to conduct clinical trials in the United States. This development marks a significant step for the company as the drug, which targets metabolism-related diseases, has already shown promising results in preclinical studies, potentially enhancing CSPC’s market position in the treatment of hypertriglyceridemia and related conditions.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company based in Hong Kong that operates in the pharmaceutical industry. It is involved in the development and production of pharmaceutical products, with a focus on innovative drugs and treatments.
YTD Price Performance: 8.47%
Average Trading Volume: 35,356
Technical Sentiment Signal: Buy
Current Market Cap: $9.11B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.